Premature ovarian insufficiency: ESHRE 2024 (with ASRM, CREWHIRL and IMS) — definition, causes and lifelong hormone therapy

A 32-year-old presents with four months of amenorrhoea, night sweats, and a positive pregnancy test that turns out negative. Her FSH comes back 38 IU/L. Your job is not to call it "early menopause" and send her away — it is to confirm POI with a second FSH at least 4 weeks later, find the cause, start hormone therapy that runs to age 51 (not to her symptom threshold), screen for Addison disease before it kills her, and walk with her through the grief of lost fertility. POI is not natural menopause shifted early; it is a different condition with a different risk-benefit calculation, and the WHI numbers do not apply to her.^[1][3]

Overview and definition

Premature ovarian insufficiency (POI) is loss of ovarian activity before the age of 40. ESHRE's 2024 evidence-based guideline (developed jointly with ASRM, CREWHIRL and IMS, with 145 recommendations) defines it clinically by menstrual disturbance plus two serum FSH levels over 25 IU/L taken at least 4 weeks apart — never on a single test.^[1][2]

The terminology has settled: POI is the preferred term. Older names — "premature ovarian failure" (POF), "primary ovarian insufficiency", "hypergonadotropic hypogonadism" — describe the same condition and you will still see them.^[1][3]

The clinical patterns are:^[1][6]

• The typical form — progressive loss of ovarian function with amenorrhoea or oligomenorrhoea and menopause-type symptoms.
• The fluctuating/intermittent form — resumption of menses and even spontaneous pregnancy is possible. This is why the diagnosis needs TWO FSH levels, weeks apart, and why you never call it irreversible on day one.

The defining insight for fellowship: POI is NOT natural menopause shifted early. A woman with POI is hypogonadal for an extra 10 to 15 years, which inverts the HRT risk-benefit calculation. For her, HRT is physiologic replacement; withholding it is the error.^[3][4]

^{[3] [6]}

References12ShowHide

1. [1]Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open, 2024.PMID 39660328
2. [2]Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod, 2016.PMID 27008889
3. [3]Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric, 2020.PMID 32896176
4. [4]Jayasena CN, Devine K, Barber K, et al. Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism. Clin Endocrinol (Oxf), 2024.PMID 39031660
5. [5]Gravholt CH, Andersen NH, Christin-Maitre S, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol, 2024.PMID 38748847
6. [6]Bachelot A, Rouxel A, Massin N, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol, 2009.PMID 19411303
7. [7]Sherman SL, Curnow EC, Easley CA, et al. Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI). J Neurodev Disord, 2014.PMID 25147583
8. [8]Crandall CJ, Mehta JM, Manson JE Management of Menopausal Symptoms: A Review. JAMA, 2023.PMID 36749328
9. [9]Davis SR, Taylor S, Hemachandra C, et al. The 2023 Practitioner's Toolkit for Managing Menopause. Climacteric, 2023.PMID 37902335
10. [10]Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017.PMID 28898378
11. [11]Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med, 2015.PMID 25686030
12. [12]Rocca WA, Grossardt BR, Shuster LT, Stewart EA Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neuro-degenerative diseases, 2012.PMID 22269187